Pharmaceutical industry news
Fresh coverage across pharma, biotech, medtech, research, approvals, and market-moving developments.
46,012 stories, page 704 of 767
🌍Industrybicara.comTier 1 · Company source
ASCO 2025 Poster Presentation: A Multicenter, Randomized, Double-Blind, Phase 2/3 Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab For First-Line Treatment of PD-L1-Positive, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: The FORTIFI-HN01 Study
Bicara TherapeuticsOriginal source
🌍Industrybicara.comTier 1 · Company source
ASCO 2025 Oral Presentation: Ficerafusp alfa with pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: Updated results from an expansion cohort of an open-label, multicenter, phase 1/1b trial
Bicara TherapeuticsOriginal source






